Mark Levick

Board member since 2025

Nationality: British-Australian

Born: 1963

Non-independent

Board committees, LEO Pharma

Chair of the Innovation Committee.

Positions and management duties

Board member of InterAx Biotech. Partner at ThaxtonPhilip (own consultancy firm).

Career

Previously CEO of Alvotech. Held senior global R&D leadership roles at GlaxoSmithKline and Novartis. Served as Senior Medical Assessor at the Medicines and Healthcare products Regulatory Agency, supporting the European Medicines Agency on anti‑infective regulation and investigational drug reviews. Previously practiced as a specialist physician in Australia and the UK.

Special competencies

Extensive clinical, regulatory and executive leadership in biotech and pharmaceutical R&D, delivering translational science and drug approval programs at GlaxoSmithKline, Novartis and Alvotech, and notably leading Alvotech’s successful public listing.